Microsoft word - pap available_products may 2013_0513-00015580-1_5-21-13.doc
Novo Nordisk Patient Assistance Program Available Products Levemir® (insulin detemir [rDNA origin] injection) • Levemir® 10 mL vials • Levemir® FlexPen® (5x3 mL) * NovoLog® (insulin aspart [rDNA origin] injection) • NovoLog® 10 mL vials • NovoLog® FlexPen® (5x3 mL) * NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) • NovoLog® Mix 70/30 10 mL vials • NovoLog® Mix 70/30 FlexPen® (5x3 mL) * Novolin® (human insulin [rDNA origin]) • Novolin® R 10 mL Vials • Novolin® N 10 mL Vials • Novolin® 70/30 10 mL Vials Disposable Needles (only available for FlexPen® and Victoza®) • NovoFine® 30G Needles (100/box) • NovoFine® 32G Tip (100/box) • NovoTwist® 30G Needle (100/box) • NovoTwist® 32G Needle (100/box) Prandin® (repaglinide tablets) • Prandin® 0.5 mg • Prandin® 1 mg • Prandin® 2 mg PrandiMet® (repaglinide/metformin HCI) tablets) • PrandiMet® 1 mg/500mg • PrandiMet® 2 mg/500mg GlucaGen® HypoKit® (glucagon [rDNA origin] for injection) • GlucaGen® HypoKit® Victoza® (liraglutide [rDNA origin] injection) • Victoza® 6mg/ml 2 x 3mL * • Victoza® 6mg/ml 3 x 3mL *
* This item is used with Novo Nordisk disposable needles. Needles will not be
Please see Important Safety Information on pages 2–5. Please see accompanying Prescribing Information. VICTOZA® (liraglutide [rDNA origin] injection) Indications and Usage
Victoza®(liraglutide [rDNA origin] injection) is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes when used along with diet and
Victoza® is not recommended as the first medication to treat diabetes. Victoza® has not been studied in patients with history of inflammation of the pancreas (pancreatitis). Victoza® is not
a substitute for insulin and has not been studied in combination with prandial (mealtime) insulin. Victoza® is not for people with type 1 diabetes or people with diabetic ketoacidosis. It is not known if Victoza® is safe and effective in children. Victoza® is not recommended for use in children.
Important Safety Information In animal studies, Victoza® caused thyroid tumors—including thyroid cancer—in some rats and mice. It is not known whether Victoza® causes thyroid tumors or a type of thyroid cancer called medullary thyroid cancer (MTC) in people, which may be fatal if not detected and treated early. Do not use Victoza® if you or any of your family members have a history of MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). While taking Victoza®, tell your doctor if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use Victoza® if you are allergic to liraglutide or any of the ingredients in Victoza®. Serious allergic reactions can happen with Victoza®. If symptoms of serious allergic reactions occur, stop taking Victoza® and seek medical attention. Pancreatitis may be severe and lead to death. Before taking Victoza®, tell your doctor if you have had pancreatitis, gallstones, a history of alcoholism, or high blood triglyceride levels since these medical conditions make you more likely to get pancreatitis.
Stop taking Victoza® and call your doctor right away if you have pain in your stomach area that is severe and will not go away, occurs with or without vomiting, or is felt going from your stomach area through to your back. These may be symptoms of pancreatitis.
Before using Victoza®, tell your doctor about all the medicines you take, especially sulfonylurea medicines or insulin, as taking them with Victoza® may affect how each medicine works. If you use Victoza® with insulin, you may give both injections in the same body area (for example, your stomach area), but not right next to each other.
Also tell your doctor if you have severe stomach problems such as slowed emptying of your stomach (gastroparesis) or problems with digesting food; have or have had kidney or liver
problems; have any other medical conditions; or are pregnant or plan to become pregnant. Tell your doctor if you are breastfeeding or plan to breastfeed. It is unknown if Victoza® will harm your unborn baby or if Victoza® passes into your breast milk. Your risk for getting hypoglycemia, or low blood sugar, is higher if you take Victoza® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. The dose
of your sulfonylurea medicine or insulin may need to be lowered while taking Victoza®.
Victoza® may cause nausea, vomiting, or diarrhea leading to dehydration, which may cause kidney failure. This can happen in people who have never had kidney problems before. Drinking plenty of fluids may reduce your chance of dehydration.
The most common side effects with Victoza® include headache, nausea, and diarrhea. Nausea is most common when first starting Victoza®, but decreases over time in most people. Immune system related reactions, including hives, were more common in people treated with Victoza® compared to people treated with other diabetes drugs in medical studies.
Please see accompanying Prescribing Information. PrandiMet® (repglinide and metformin HCI) Indications and Usage
PrandiMet® (repaglinide and metformin HCl) is a combination of two drugs, repaglinide, which belongs to the meglitinide class of diabetes medications, and metformin HCl. PrandiMet® is used along with diet and exercise to control high blood sugar in adult patients with type 2 diabetes who are already being treated with a meglitinide and metformin, or who have inadequate blood sugar control while taking either meglitinide alone or metformin alone.
PrandiMet® should not be used to treat type 1 diabetes or diabetic ketoacidosis, a
complication of diabetes resulting in a buildup of ketones (a by-product of fat breakdown) in the body.
Important Safety Information WARNING: LACTIC ACIDOSIS Lactic acidosis (too much lactic acid in the body) can occur due to the buildup of metformin in the body. The risk increases in patients who are dehydrated or drink too much alcohol, have blood infections, kidney or liver problems, and heart failure. Some of the symptoms include tiredness or weakness, muscle pain, trouble breathing, increasing sleepiness, and abdominal problems. If you think you may have acidosis, stop taking PrandiMet® and get medical help right away.
PrandiMet® should not be used if you: have kidney problems; have metabolic acidosis (excessive acidity of the blood), including diabetic ketoacidosis; take gemfibrozi; or are
allergic to repaglinide, metformin HCl, or any of its ingredients.
You should only take PrandiMet® if your kidneys are working properly. Your kidney function tests should be checked before starting PrandiMet® and at least once a year afterwards. You should stop taking PrandiMet® if you develop kidney problems.
PrandiMet® should be temporarily stopped if you need to take certain tests with injectable dyes or contrast agents. PrandiMet® should also be replaced with insulin when your blood sugar control is poor because of stress or when you eat less foods or liquids, such as during
You should not take PrandiMet® if you have liver problems or with NPH insulin. Do not drink too much alcohol when taking PrandiMet®.
You should start taking PrandiMet® at the lowest dose if you have never taken a meglitinide before.
You should have blood tests every year to check for Vitamin B12 deficiency.
There are no studies showing that PrandiMet® or any other diabetes drugs taken by mouth
reduce the risk for stroke and heart attack. In a study of patients taking repaglinide and metformin together, the most common side effects reported were low blood sugar (hypoglycemia), headache, diarrhea, nausea, and
infections of the nose, ears, and throat. Please see accompanying Prescribing Information.
FlexPen®, GlucaGen®, HypoKit®, Levemir®, Novolin®, NovoFine®, NovoLog®, NovoTwist®,
Prandin®, PrandiMet®, and Victoza® are registered trademarks of Novo Nordisk A/S. 2013 Novo Nordisk Printed in the U.S.A. 0513-00015580-1 May 2013
Culture and Biology CONCORDIA UNIVERSITY Anthropology 203/4 A Winter 2012 Monday/Wednesday 8:45-10:00 am - Rm: H-557 Professor: Salinda S. Hess, PhD Office hours: 11-noon Mon/Wed or by appt. This course is based on the framework of an introduction to physical anthropology, as indicated in the outline below; however, bicultural anthropology will provide the impetus
Novo Nordisk Patient Assistance Program